On January 5, Novo Nordisk began selling the oral version of Wegovy — semaglutide in pill form, no injection required — to American self-pay patients at $149 per month. [1] The price was celebrated as a breakthrough. Reuters called it "a fraction of the drug's previous cost." CNBC reported a "new wave of patients" flooding GLP-1 prescribers. [2] The $149 figure appeared in presidential social media posts, pharmaceutical analyst notes, and health policy presentations as evidence that the obesity drug revolution was finally becoming affordable.

Tomorrow, April 15, the price rises to $199 per month. [3]

Novo Nordisk disclosed the increase in the January launch announcement itself, in language designed to be overlooked. The $149 price was described as an "introductory" rate for the first quarter. [1] The word "introductory" did the work of converting a temporary promotion into a permanent narrative. By the time the price rises thirty-four percent, millions of patients will have established the habit, built the pill into their daily routine, and — in many cases — already lost enough weight that discontinuation carries medical and psychological risk. The clinical literature on GLP-1 discontinuation is unambiguous: patients who stop semaglutide regain approximately two-thirds of lost weight within a year. [2]

The three signals arriving simultaneously make the Wegovy pill story more complicated than a straightforward price complaint.

Signal one: the science is getting stronger. A Lancet Psychiatry study published in March reported that patients taking GLP-1 receptor agonists for type 2 diabetes showed forty-two percent lower rates of mental health deterioration compared to matched controls. [4] The finding was striking not because semaglutide is known to cross the blood-brain barrier — it does, modestly — but because the effect size was larger than any psychopharmaceutical intervention for the same population. Depression, anxiety, and cognitive decline all improved. The researchers cautioned that the study was observational, not randomized, and that confounding factors — weight loss itself improves mood, better glycemic control reduces neuroinflammation — make causal attribution premature. But the signal is strong enough that Novo Nordisk and Eli Lilly have both initiated psychiatric outcome trials for their GLP-1 drugs.

Signal two: the safety questions are getting louder. The FDA confirmed in March that it is evaluating reports of suicidal ideation among patients taking semaglutide, particularly in the first twelve weeks of treatment. [2] The evaluation is preliminary — the agency has not issued a warning, a black-box label, or a prescribing restriction. But the investigation's existence creates an information environment where patients are simultaneously hearing that GLP-1 drugs may protect their mental health and that GLP-1 drugs may endanger it. Both claims have evidentiary support. Neither is conclusive. The gap between them is where patient anxiety lives.

Signal three: public insurance is arriving, slowly. The Medicare GLP-1 Bridge program, announced in February, will offer semaglutide to qualifying beneficiaries at $50 per month starting in July. [2] The program is limited — it covers only patients with a BMI above 35 and a comorbid diagnosis of type 2 diabetes or cardiovascular disease, a population of approximately 4.2 million Medicare enrollees. It does not cover the broader obesity indication that drives most Wegovy prescriptions. And $50 per month, while dramatically lower than the $199 self-pay price or the $1,349 list price, still represents a meaningful cost for seniors on fixed incomes.

The insurance coverage gap is the structural problem. Industry data suggests that only about twenty percent of GLP-1 prescriptions are covered by commercial insurance. [3] The remaining eighty percent are self-pay, employer-sponsored wellness programs, or telehealth platforms like Ro and Hims that have built entire business models around facilitating GLP-1 access outside the traditional insurance framework. The $149-to-$199 increase matters most for this population — the uninsured or underinsured patients who chose the oral pill specifically because it was cheaper than the $249 injection and did not require a specialty pharmacy.

The bait-and-switch framing is crude but not inaccurate. Novo Nordisk used $149 to capture market share during the pill's launch quarter, when competition from Eli Lilly's oral tirzepatide was still months away. The introductory price generated headlines, attracted patients, and established the oral semaglutide category in a market that had previously known GLP-1 drugs only as injectables. Now that the category exists and the patients are enrolled, the price rises. The pharmaceutical industry has a name for this strategy: "access pricing followed by value pricing." Patients have a different name for it.

The deeper question is what the Wegovy pill represents in the American healthcare economy. At $199 per month — $2,388 per year — oral semaglutide is cheaper than most branded medications for chronic conditions. It is cheaper than many insulin regimens. It is dramatically cheaper than the bariatric surgery it replaces for some patients. By the standards of American drug pricing, $199 is reasonable. By the standards of the patients who started at $149 three months ago and now face a thirty-four percent increase, it is a broken promise.

The Lancet data, the FDA investigation, the Medicare Bridge, and the price hike all arrive in the same month. They point in four different directions. The science says GLP-1 drugs may be the most important pharmacological development since statins. The safety signal says we do not fully understand what they do to the brain. The public insurance program says the government recognizes the drugs' value but will ration access. And the price increase says the manufacturer recognizes the drugs' value too — and intends to capture it.

Tomorrow the pill costs $199. The patients who started at $149 will decide whether fifty dollars a month is the price of a broken promise or the cost of a drug that might protect their hearts, their weight, and — if the Lancet is right — their minds. Most of them will pay.

-- NORA WHITFIELD, Chicago